01—Abstract
Summary
Summary of the 10-Q filed May 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson reported a strong first quarter for fiscal year 2024, with total sales reaching $21.4 billiona, a 2.3% increase year-over-year, driven by robust operational growth of 3.9%.
The company returned to profitability with net earnings of $3.3 billionb, a significant improvement from a net loss of $68 million in the prior year's first quarter. This rebound was largely influenced by a substantial reduction in legal charges, particularly related to talc matters, which decreased from $6.9 billion to $2.7 billion year-over-year. The Innovative Medicine segment showed resilience with a 1.1% sales increase, supported by strong performance in Oncology and Pulmonary Hypertension, while the MedTech segment saw a 4.5% sales boost, led by growth in Cardiovascular and Orthopaedics.
Despite some headwinds, including a decline in COVID-19 vaccine revenue and ongoing biosimilar competition for key products, Johnson & Johnson demonstrated effective operational management and strategic execution. The company also continued its commitment to shareholder returns by declaring a quarterly dividend and actively repurchasing shares. The pending acquisition of Shockwave Medical, a significant move within the MedTech segment, signals a continued focus on strategic growth and portfolio enhancement.
02—Key points
Key Highlights
- Total sales increased by 2.3% to $21.4 billion, with operational growth of 3.9%, excluding currency impacts.
- Net earnings improved significantly to $3.3 billion from a net loss of $68 million in the prior year's quarter.
- The Innovative Medicine segment achieved sales of $13.6 billion, up 1.1% operationally, driven by strong performance in Oncology and Pulmonary Hypertension.
- The MedTech segment reported sales of $7.8 billion, a 4.5% increase, with notable growth in Cardiovascular and Orthopaedics.
- Earnings before taxes swung to a profit of $3.7 billion from a loss of $1.3 billion in the prior year, significantly aided by a reduction in talc litigation charges.
- The company announced a definitive agreement to acquire Shockwave Medical for approximately $13.1 billion, strengthening its MedTech offerings.
- Cash and cash equivalents increased to $25.5 billion, providing substantial liquidity for operations and strategic initiatives.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Johnson & Johnson kept $0.15.
- Revenue$21.38B100.0%
- Cost of revenue−$6.51B30.4%
- Gross profit$14.87B69.6%
- Operating costs−$11.62B54.3%
- Operating income$3.25B15.2%
- Interest, other & tax$-00.0%
- Net income$3.25B15.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 1, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $21.38B$19.94B | +7.2% |
| Cost of Revenue | $6.51B— | — |
| Gross Profit | $14.87B$13.86B | +7.3% |
| SG&A Expenses | $5.26B— | — |
| Operating Income | $3.25B$3.23B | +0.9% |
| Interest Expense | $155.00M— | — |
| Net Income | $3.25B$3.52B | −7.5% |
| EPS (Basic) | $1.35$1.35 | 0.0% |
| EPS (Diluted) | $1.34$1.33 | +0.8% |
| Shares Outstanding (Basic) | 2.41B— | — |
| Shares Outstanding (Diluted) | 2.43B— | — |
05—Questions
Frequently Asked Questions
What drove the significant increase in net earnings this quarter?
The significant increase in net earnings, from a loss of $68 million to a profit of $3.3 billion, was primarily driven by a substantial reduction in legal charges, particularly those related to talc litigation, which decreased from $6.9 billion in the prior year's quarter to $2.7 billion in the current quarter. Additionally, the company's core business segments, Innovative Medicine and MedTech, showed positive sales growth.
How did the company's two main segments perform?
The Innovative Medicine segment reported sales of $13.6 billion, a 1.1% increase year-over-year, bolstered by strong performance in Oncology and Pulmonary Hypertension, although partially offset by declines in Infectious Diseases due to lower COVID-19 vaccine revenue. The MedTech segment saw sales of $7.8 billion, up 4.5%, with strong growth in Cardiovascular and Orthopaedics, partly due to a timing change in revenue recognition for certain Orthopaedics products.
What is the strategic significance of the Shockwave Medical acquisition?
The planned acquisition of Shockwave Medical for approximately $13.1 billion is a significant strategic move to bolster Johnson & Johnson's MedTech portfolio, particularly in the cardiovascular space. Shockwave's innovative intravascular lithotripsy technology is expected to enhance J&J's offerings in treating calcified cardiovascular diseases, aligning with the company's strategy to invest in high-growth areas.
What is the company's outlook regarding its significant legal liabilities?
Johnson & Johnson is actively working towards resolving its major legal liabilities. The company has recorded significant reserves for talc-related claims and is pursuing a "prepackaged" chapter 11 bankruptcy plan for a comprehensive resolution. Opioid litigation settlement payments are ongoing. While these liabilities represent substantial financial commitments, the company has indicated that resolutions are in progress and the financial impact is being managed through accruals and strategic plans.
06—Continue